Ignite Creation Date:
2025-12-26 @ 10:20 PM
Ignite Modification Date:
2025-12-26 @ 10:20 PM
Study NCT ID:
NCT03298412
Status:
TERMINATED
Last Update Posted:
2020-09-11
First Post:
2017-09-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
Sponsor:
Amgen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-23
Start Date Type:
ACTUAL
Primary Completion Date:
2019-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-09-30
Completion Date Type:
ACTUAL
First Submit Date:
2017-09-12
First Submit QC Date:
None
Study First Post Date:
2017-10-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2020-08-20
Results First Submit QC Date:
None
Results First Post Date:
2020-09-11
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-09-10
Last Update Post Date:
2020-09-11
Last Update Post Date Type:
ACTUAL